Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
161Tb-LNC1011 in Metastatic Castration-Resistant Prostate Cancer
NCT07381582Phase 1Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jan 2026
- Primary completion
- Oct 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 161Tb-LNC1011 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Peking Union Medical College Hospital. Primary endpoints: Dose-Limiting Toxicities at 6 weeks, Maximum Tolerated Dose and 1 more. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
161Tb-LNC1011
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07381582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07381582.